GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » Operating Income

Penumbra (Penumbra) Operating Income : $96 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Penumbra Operating Income?

Penumbra's Operating Income for the three months ended in Mar. 2024 was $12 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $96 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Penumbra's Operating Income for the three months ended in Mar. 2024 was $12 Mil. Penumbra's Revenue for the three months ended in Mar. 2024 was $279 Mil. Therefore, Penumbra's Operating Margin % for the quarter that ended in Mar. 2024 was 4.34%.

Penumbra's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Penumbra's annualized ROC % for the quarter that ended in Mar. 2024 was 3.20%. Penumbra's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.19%.


Penumbra Operating Income Historical Data

The historical data trend for Penumbra's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra Operating Income Chart

Penumbra Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.51 -38.94 -7.50 6.08 91.77

Penumbra Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.01 17.89 30.84 35.03 12.10

Penumbra Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Penumbra  (NYSE:PEN) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Penumbra's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=48.404 * ( 1 - 24.78% )/( (1136.393 + 1136.04)/ 2 )
=36.4094888/1136.2165
=3.20 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1556.305 - 130.725 - ( 289.187 - max(0, 151.144 - 915.402+289.187))
=1136.393

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1579.845 - 130.331 - ( 313.474 - max(0, 152.803 - 935.023+313.474))
=1136.04

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Penumbra's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=48.404/( ( (300.439 + max(488.505, 0)) + (291.823 + max(482.546, 0)) )/ 2 )
=48.404/( ( 788.944 + 774.369 )/ 2 )
=48.404/781.6565
=6.19 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(201.768 + 388.023 + 36.424) - (130.725 + 6.985 + 0)
=488.505

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(191.989 + 398.366 + 31.194) - (130.331 + 8.672 + 0)
=482.546

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Penumbra's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=12.101/278.655
=4.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Penumbra Operating Income Related Terms

Thank you for viewing the detailed overview of Penumbra's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Penumbra (Penumbra) Business Description

Traded in Other Exchanges
Address
One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Executives
Harpreet Grewal director C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Surbhi Sarna director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts officer: EVP, Gen. Counsel & Secretary PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Adam Elsesser director, officer: Chairman, CEO and President 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Don W. Kassing director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Thomas Wilder director 2 MUSICK, IRVINE CA 92618
Arani Bose director, officer: Chief Innovator 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lynn Rothman officer: EVP and Chief Business Officer 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray officer: President, International 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju officer: CFO and Head of Strategy 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Maggie Yuen officer: Chief Financial Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Lambert Shiu officer: Chief Accounting Officer ONE PENUMBRA PLACE, ALAMEDA CA 94502
Janet Leeds director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans officer: EVP, Gen. Counsel & Secretary ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502